Literature DB >> 14617286

Hyperbaric oxygen therapy of diabetic foot ulcers, transcutaneous oxymetry in clinical decision making.

Juha Niinikoski1.   

Abstract

The foot ulcer is one of most common and devastating complications of diabetes and is associated with considerable morbidity and mortality. The major causes of these ulcers are ischemia/hypoxia, neuropathy, and infection, and they often coexist. Despite conventional therapy including revascularization procedures when appropriate, three situations lead frequently to amputation: persistent critical limb ischemia, soft tissue infection, and impaired wound healing from osteomyelitis. In these conditions, hyperbaric oxygen therapy may be used as an adjunctive treatment and is associated with a better outcome. Randomized, prospective, controlled trails have shown the benefit of hyperbaric oxygen therapy in diabetic ulcers of the lower extremity. Transcutaneous oxygen measurement performed under hyperbaric oxygen therapy has a prognostic significance when used to select patients who are the most likely to benefit from therapy. Hyperbaric oxygen should be added to conventional treatment if the transcutaneous oxygen tension close to the trophic lesion in 2.5 ATA hyperbaric oxygen is over 200 mmHg. Peri-wound transcutaneous oxygen tensions over 400 mmHg in 2.5 ATA hyperbaric oxygen or over 50 mmHg in normobaric pure oxygen predict healing success with adjuncted hyperbaric oxygen therapy with high accuracy.

Entities:  

Mesh:

Year:  2003        PMID: 14617286     DOI: 10.1046/j.1524-475x.2003.11610.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  10 in total

1.  Intracellular delivery of adenosine triphosphate enhanced healing process in full-thickness skin wounds in diabetic rabbits.

Authors:  Jianpu Wang; Rong Wan; Yiqun Mo; Ming Li; Qunwei Zhang; Sufan Chien
Journal:  Am J Surg       Date:  2010-06       Impact factor: 2.565

2.  Enhancing skin wound healing by direct delivery of intracellular adenosine triphosphate.

Authors:  Benjamin Chiang; Eric Essick; William Ehringer; Sidney Murphree; Mary Anne Hauck; Ming Li; Sufan Chien
Journal:  Am J Surg       Date:  2007-02       Impact factor: 2.565

Review 3.  Macrophage Differentiation in Normal and Accelerated Wound Healing.

Authors:  Girish J Kotwal; Sufan Chien
Journal:  Results Probl Cell Differ       Date:  2017

4.  A challenging journey of maxillofacial implants placement and rehabilitation in an irradiated exenterated socket.

Authors:  Radhika Jain; Modhupa Ghosh; Ruchi Goel; Rekha Gupta; Priyanka Golhait; Basudeb Ghosh
Journal:  J Oral Biol Craniofac Res       Date:  2022-04-04

5.  Hyperbaric oxygen therapy for diabetic foot wounds: has hope hurdled hype?

Authors:  Benjamin A Lipsky; Anthony R Berendt
Journal:  Diabetes Care       Date:  2010-05       Impact factor: 19.112

Review 6.  Management of diabetic foot: Brief synopsis for busy orthopedist.

Authors:  Tae Hwan Park; Ashish Anand
Journal:  J Clin Orthop Trauma       Date:  2014-11-14

Review 7.  Wound healing essentials: let there be oxygen.

Authors:  Chandan K Sen
Journal:  Wound Repair Regen       Date:  2009 Jan-Feb       Impact factor: 3.617

8.  Intracellular adenosine triphosphate delivery enhanced skin wound healing in rabbits.

Authors:  Jianpu Wang; Qunwei Zhang; Rong Wan; Yiqun Mo; Ming Li; Michael T Tseng; Sufan Chien
Journal:  Ann Plast Surg       Date:  2009-02       Impact factor: 1.539

9.  Evaluation of the efficacy of hyperbaric oxygen therapy in the management of chronic nonhealing ulcer and role of periwound transcutaneous oximetry as a predictor of wound healing response: A randomized prospective controlled trial.

Authors:  Sarbjot Kaur; Mridula Pawar; Neerja Banerjee; Rakesh Garg
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-01

10.  Rapid granulation tissue regeneration by intracellular ATP delivery--a comparison with Regranex.

Authors:  Jeffrey D Howard; Harshini Sarojini; Rong Wan; Sufan Chien
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.